A Single-arm Single-center Trial of Bridging GPRC5D/CD3 Bispecific Antibody Treatment With BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

NCT07185477 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Relapsed/Refractory Multiple Myeloma (RRMM)

Interventions

BIOLOGICAL: QLS32015

Sponsor

Institute of Hematology & Blood Diseases Hospital, China